Therapeutic area intelligence for Iron Replacement with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

AZURITY →

Recent signals(2)

RegulatoryAugust 11, 2026

FDA Accepts Supplement for FERAHEME by AZURITY

The FDA has accepted a supplemental application for FERAHEME (ferumoxytol) submitted by AZURITY, with a standard review priority.

RegulatoryJuly 21, 2026

FDA Accepts Supplement for FERAHEME by AZURITY

The FDA has accepted a supplemental application for FERAHEME, an iron replacement therapy.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.